Is there an optimal parathyroid hormone level in end-stage renal failure: The lower the better?

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 3, 2001, Pages 421-427

  Sakhaee, Khashayar ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

BONE DISEASE; BONE REMODELING; BONE TURNOVER; CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY DISEASE; HEART DEATH; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RESISTANCE; HUMAN; HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SKELETON; VALVULAR HEART DISEASE;

BONE AND BONES; CALCINOSIS; HUMANS; KIDNEY FAILURE; PARATHYROID HORMONE;

EID: 0035022845     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200105000-00020     Document Type: Review

References (81)

1. Role of uremia in the skeletal resistance to the calcemic action of parathyroid hormone
2. Skeletal resistance to parathyroid hormone in renal failure: Studies in 105 human subjects
3. Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism
4. 3, and radiology in end-stage renal disease
5. The spectrum of bone disease in endstage failure: An evolving disorder
6. Intact parathyroid hormone over-estimates the presence and severity of parathyroid mediated osseous abnormalities in uremia
7. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence for a better response to PTH
8. 3 inhibits parathyroid cell proliferation in experimental uremia
9. 3 in experimental renal hyperparathyroidism
10. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
11. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol treatment
12. Aplastic osteodystrophy without aluminum: The role of 'suppressed' parathyroid function
13. Editorial: Skeletal growth factors and aging
14. Skeletal growth factors
15. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures
16. Parathyroid hormone enhances the transcript and polypeptide levels of insulin growth factor-I in osteoblast enriched cultures from fetal rat bone
17. Parathyroid hormone modulates transforming growth factor β activity and binding in osteoblast-enriched cell cultures from fetal rat parietal bone
18. Coordinate regulation of PTH/PTHrp receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells
19. Growth of long bones in renal failure: Roles of hyperparathyroidism, growth hormone and calcitriol
20. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis
21. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD
22. Relationship between intact 1-84 PTH parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity
23. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
24. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
25. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients
26. New therapies raise new issues for lowering parathyroid hormone levels in uremic patients
27. Vitamin D, parathyroid hormone, and the renal osteodystrophy
28. Bone aluminum and histomorphometric features of renal osteodystrophy
29. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy
30. Effect of aluminum on bone cell localization
31. Low bone turnover in patients with renal failure
32. New concepts in renal osteodystrophy
33. A: Non-aluminic adynamic bone disease in non-dialyzed uremic patients: A new type of osteodystrophy due to over treatment?
34. Risk factors for renal osteodystrophy: A multivariant analysis
35. Risk for adynamic bone disease in dialyzed patients
36. Is aplastic osteodystrophy a disease of malnutrition
37. Is there a link between erythropoietin therapy and adynamic bone disease
38. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
39. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study
40. Risk factors for vertebral fractures in renal osteodystrophy
41. Increased risk of hip fracture among patients with end-stage renal disease
42. Risk factors for hip fractures among patients with end-stage renal disease
43. Aplastic osteodystrophy follow-up after five years
44. Parathyroid hormone deficiency is an indicator of poor nutritional state and prognosis in dialysis patients
45. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia
46. Prognostic value of enrollment nutritional markers including novel predictors PTH and prealbumin in hemodialysis patients: Twelve years of follow-up
47. Correlates of survival in peritoneal dialysis: Fifteen years of follow-up
48. Update on renal osteodystrophy: Pathogenesis and clinical management
49. Identifiction of a lower molecular weight inhibitor of osteoblast mitogenesis in uremic plasma
50. Interleukin-11 inhibits bone formation in vitro
51. Increased circulating osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) in patients with chronic renal failure
52. Anabolic actions of parathyroid hormone on bone
53. Insulin-like growth factor 1 mediates selective anabolic effects of parathyroid hormone in bone cultures
54. Parathyroid hormone stimulates the proliferation of cells derived from human bone
55. PTH/PTHrp receptor mRNA is downregulated in epiphyseal cartilage-growth plate of uremic rats
56. The renal PTH/PTHrp receptor is down-regulated in rats with chronic renal failure
57. Cellular mechanisms of renal osteodystrophy
58. Parathyroid hormone increases the concentration of insulin-like growth factor 1 and transforming growth factor β in rat bone
59. Growth hormone, the insulin-like growth factor system and the kidney
60. Impaired action of insulin-like growth factor-1 on protein synthesis and degradations in skeletal muscle of rats with chronic renal failure: Evidence for a post-receptor defect
61. The effects of cytokines and growth factors on osteoblastic cells
62. Hormonal control of bone collagen synthesis in vitro: Inhibitory effect of 1-hydroxylated vitamin D metabolites
63. 3 and dexamethasone on rat osteoblast-like primary cell cultures: Receptor occupancy and functional expression patterns for three different bioresponses
64. Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease
65. 22-Oxalcalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
66. New concepts in renal osteodystrophy
67. Interleukin-11 inhibits bone formation in vitro
68. Interleukin-4 as a potent inhibitor of bone resorption
69. Is parathyroid hormone a uremic toxin?
70. Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism
71. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
72. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
73. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients
74. Coronary artery disease: Prediction with in vitro electron beam CT
75. Coronary calcium, as determimed by electron beam computed tomography, and coronary disease on arteriogram: Effect of patient's sex on diagnosis
76. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uremia: Evidence for a permissive action of PTH
77. Atherosclerosis in uremia. Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation
78. The influence of hyperparathyroidism on glucose metabolism in uremia
79. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurement in renal failure
80. Reversibility of parathyroid gland suppression in CAPD patients with low I-PTH levels
81. Calcium-sensing receptor and calcimimetic agents